News of Note—Novartis backs out of Akcea/Ionis research deal; Flagship jumps on gene therapy bandwagon

Christmas tree
News from around the biotech world as we look toward the Christmas break (Shutterstock/Liaskin Aleksei)

> After its near $10 billion buyout of The Medicines Company and its accompanying next-gen heart drug hopeful, Novartis has opted to back away from its Akcea/Ionis research deal for their familial chylomicronemia syndrome drug AKCEA-APOCIII-LRx. Akcea gets back full rights and plans to announced new phase 2 data next year.

> Venture capital firm and biotech incubator Flagship Pioneering has jumped on the gene therapy bandwagon with a new startup up of its own: Ring Therapeutics, an early-stage biotech developing first-in-class gene therapies using a new viral vector platform. The new company gets $50 million and Flagship’s guiding hand. It will focus on genetic disorders, ophthalmology, oncology, metabolic disorders, hematology, central nervous system disorders and inflammatory diseases.

> After spending a small $45 million upfront fee for a tau Alzheimer’s disease prospect this week, Biogen has made another bolt-on asset deal, this time with Catalyst Bio for its pegylated CB 2782, which is targeting several eye conditions including dry age-related macular degeneration. The deal is $15 million with $340 million tied up in biobucks.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

Check back Monday, Dec. 23, for more of the day's biggest news and a special issue where we look back on your most read stories of the year.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.